Opiate Dependence disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: OPT003 MIFTS: 54	Opiate Dependence Categories: Mental diseases
Genes Tissues Related diseases Publications Pathways Drugs Download Expand all tables

Sources

Aliases & Classifications for Opiate Dependence

MalaCards integrated aliases for Opiate Dependence:

Name: Opiate Dependence ¹² ¹⁵

Opioid-Related Disorders ⁴⁴ ⁷³

Opioid Dependence ⁷⁶ ⁵⁵

Opioid Type Dependence ¹²

Opiate Addiction ⁷³

Classifications:

MalaCards categories:
Anatomical: Mental diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Mental and behavioural disorders

Mental and behavioural disorders due to psychoactive substance use

Mental and behavioural disorders due to use of opioids

Mental and behavioural disorders due to use of opioids: Dependence syndrome

External Ids:

Disease Ontology ¹² DOID:2559

ICD10 ³³ F11.2

ICD9CM ³⁵ 304.0 304.00

MeSH ⁴⁴ D009293

SNOMED-CT ⁶⁸ 191817000 191818005 192220003 more

UMLS ⁷³ C0524662 C0027412

Sources

Summaries for Opiate Dependence

Disease Ontology : ¹² A drug dependence that involves the continued use of opiate drugs despite despite problems related to use of the substance.

MalaCards based summary : Opiate Dependence, also known as opioid-related disorders, is related to opioid dependence 1 and morphine dependence. An important gene associated with Opiate Dependence is ODS1 (Opioid Dependence, Susceptibility To, 1), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Buprenorphine and Heroin have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and skin, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : ⁷⁶ Opioid use disorder is a medical condition characterized by a problematic pattern of opioid use that... more...

Sources

Related Diseases for Opiate Dependence

Diseases related to Opiate Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 89)

#	Related Disease	Score	Top Affiliating Genes
1	opioid dependence 1	34.0	ODS1 OPRM1
2	morphine dependence	30.5	OPRD1 OPRK1 OPRM1
3	opioid addiction	29.7	DRD2 OPRD1 OPRK1 OPRM1
4	personality disorder	29.5	DRD2 DRD3 SLC6A4 TPH1
5	heroin dependence	29.4	DRD2 OPRD1 OPRM1 PDYN
6	schizophrenia	28.2	DRD2 DRD3 SLC6A4 TH TPH1
7	disease of mental health	27.6	DRD2 DRD3 OPRM1 PDYN POMC SLC6A4
8	alcohol dependence	25.1	DRD2 DRD3 OPRD1 OPRK1 OPRM1 PDYN
9	obsessive-compulsive personality disorder	10.8	DRD3 SLC6A4
10	acidophil adenoma	10.6	IGF1 POMC
11	pituitary infarct	10.6	IGF1 POMC
12	sick building syndrome	10.6	POMC VEGFA
13	empty sella syndrome	10.5	IGF1 POMC
14	sheehan syndrome	10.5	IGF1 POMC
15	toxic encephalopathy	10.4	CREB1 NGF TH
16	cerebral hypoxia	10.4	CREB1 IGF1
17	mental depression	10.4	POMC SLC6A4 TPH1
18	hyperpituitarism	10.4	IGF1 POMC
19	chronic fatigue syndrome	10.3	IGF1 POMC SLC6A4
20	alcohol-induced mental disorder	10.3	DRD2 SLC6A4
21	panic disorder	10.3	POMC SLC6A4 TPH1
22	west syndrome	10.3	POMC TH TPH1
23	anorexia nervosa	10.3	IGF1 POMC SLC6A4
24	pituitary tumors	10.3	IGF1 POMC VEGFA
25	polysubstance abuse	10.3	DRD2 DRD3
26	nervous system disease	10.3	NGF TH VEGFA
27	retrograde amnesia	10.3	PDYN POMC SLC6A4
28	tardive dyskinesia	10.2	DRD2 DRD3
29	phobic disorder	10.2	OPRK1 SLC6A4
30	prolactin producing pituitary tumor	10.2	DRD2 NGF
31	impulse control disorder	10.2	DRD2 DRD3
32	galactorrhea	10.2	DRD2 IGF1
33	alcoholic psychosis	10.2	DRD2 SLC6A4
34	pathological gambling	10.2	DRD2 DRD3 SLC6A4
35	migraine without aura	10.2	DRD2 DRD3 SLC6A4
36	somatoform disorder	10.1	NGF OPRM1 TPH1
37	delusional disorder	10.1	DRD2 DRD3 TH
38	pheochromocytoma	10.1	CREB1 NGF POMC TH
39	aging	10.1
40	substance abuse	10.1	DRD2 DRD3 SLC6A4
41	alcohol abuse	10.1	DRD2 DRD3 SLC6A4
42	schizoaffective disorder	10.1	DRD2 DRD3 SLC6A4
43	depression	10.1
44	cutaneous solitary mastocytoma	10.1	PDYN POMC
45	social phobia	10.1	DRD2 SLC6A4
46	eating disorder	10.1	DRD2 POMC SLC6A4
47	movement disease	10.0	DRD2 DRD3 TH
48	hypothyroidism, congenital, nongoitrous, 4	10.0	IGF1 POMC
49	generalized anxiety disorder	10.0	DRD2 SLC6A4 TPH1
50	conduct disorder	10.0	DRD2 SLC6A4 TPH1

Graphical network of the top 20 diseases related to Opiate Dependence:

Sources

Symptoms & Phenotypes for Opiate Dependence

MGI Mouse Phenotypes related to Opiate Dependence:

⁴⁶ (show all 14)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	behavior/neurological	MP:0005386	10.34	DRD2 NGF DRD3 OPRD1 CREB1 OPRM1
2	homeostasis/metabolism	MP:0005376	10.28	IGF1 DRD2 NGF DRD3 CREB1 OPRK1
3	growth/size/body region	MP:0005378	10.23	IGF1 DRD2 NGF DRD3 CREB1 OPRM1
4	cardiovascular system	MP:0005385	10.21	CREB1 IGF1 DRD2 NGF DRD3 POMC
5	integument	MP:0010771	10.18	IGF1 DRD2 NGF OPRD1 OPRM1 SLC6A4
6	endocrine/exocrine gland	MP:0005379	10.13	CREB1 IGF1 DRD2 OPRK1 POMC SLC6A4
7	adipose tissue	MP:0005375	10.08	IGF1 DRD2 DRD3 POMC OPRM1 PDYN
8	mortality/aging	MP:0010768	10.07	CREB1 IGF1 DRD2 NGF DRD3 POMC
9	nervous system	MP:0003631	10.07	IGF1 DRD2 NGF DRD3 OPRD1 CREB1
10	digestive/alimentary	MP:0005381	9.97	DRD2 DRD3 OPRK1 OPRM1 PDYN VEGFA
11	muscle	MP:0005369	9.87	CREB1 IGF1 DRD2 NGF SLC6A4 TPH1
12	no phenotypic analysis	MP:0003012	9.76	DRD2 NGF OPRM1 TH PDYN OPRD1
13	normal	MP:0002873	9.56	CREB1 IGF1 DRD2 NGF SLC6A4 OPRM1
14	respiratory system	MP:0005388	9.1	CREB1 IGF1 DRD2 TPH1 VEGFA TH

Sources

Drugs & Therapeutics for Opiate Dependence

Drugs for Opiate Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 323)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Buprenorphine

Approved, Illicit, Investigational, Vet_approved

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

52485-79-7

40400 644073

Heroin

Approved, Illicit, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

561-27-3

5462328

Guaifenesin

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

93-14-1

3516

Methadone

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

76-99-3

4095

Naloxone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

465-65-6

5284596

Naltrexone

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

16590-41-3

5360515

Nicotine

Approved

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

54-11-5

942 89594

Ethanol

Approved

Phase 4,Phase 3,Phase 2,Not Applicable

64-17-5

702

Dopamine

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

51-61-6, 62-31-7

681

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

437-38-7

3345

Cocaine

Approved, Illicit

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

50-36-2

5760 446220

Peginterferon alfa-2b

Approved

Phase 4

99210-65-8, 215647-85-1

Ribavirin

Approved

Phase 4,Phase 3,Not Applicable

36791-04-5

37542

Ketamine

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Not Applicable

6740-88-1

3821

Valproic Acid

Approved, Investigational

Phase 4,Not Applicable

99-66-1

3121

Norepinephrine

Approved

Phase 4,Phase 1,Phase 2

51-41-2

439260

Dexmedetomidine

Approved, Vet_approved

Phase 4,Phase 3

113775-47-6

68602 5311068

Lidocaine

Approved, Vet_approved

Phase 4,Phase 3,Not Applicable

137-58-6

3676

Oxycodone

Approved, Illicit, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

76-42-6

5284603

Buspirone

Approved, Investigational

Phase 4

36505-84-7

2477

Benzocaine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

1994-09-7, 94-09-7

2337

Morphine

Approved, Investigational

Phase 4,Phase 3,Phase 1,Phase 2

57-27-2

5288826

Gabapentin

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

60142-96-3

3446

gamma-Aminobutyric acid

Approved, Investigational

Phase 4,Phase 2,Not Applicable

56-12-2

119

Sofosbuvir

Approved

Phase 4

1190307-88-0

45375808

Isoniazid

Approved, Investigational

Phase 4

54-85-3

3767

Rifapentine

Approved, Investigational

Phase 4

61379-65-5

6323497

Bupivacaine

Approved, Investigational

Phase 4,Phase 2,Phase 3

2180-92-9, 38396-39-3

2474

Acetazolamide

Approved, Vet_approved

Phase 4,Phase 2

59-66-5

1986

Remifentanil

Approved

Phase 4,Phase 3

132875-61-7

60815

Menthol

Approved

Phase 4,Not Applicable

2216-51-5

16666

Oxymorphone

Approved, Investigational, Vet_approved

Phase 4

76-41-5

5284604

tannic acid

Approved, Nutraceutical

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Analgesics

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Analgesics, Opioid

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Central Nervous System Depressants

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Narcotic Antagonists

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Narcotics

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Opiate Alkaloids

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Peripheral Nervous System Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Antitussive Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Chlorpheniramine, phenylpropanolamine drug combination

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Respiratory System Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Buprenorphine, Naloxone Drug Combination

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Anti-Infective Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Anesthetics

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Anesthetics, General

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Anesthetics, Intravenous

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Excitatory Amino Acid Antagonists

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Excitatory Amino Acids

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 598)

#	Name	Status	NCT ID	Phase	Drugs
1	Buprenorphine and Integrated HIV Care Evaluation	Unknown status	NCT00124358	Phase 4	Buprenorphine
2	Integrating Buprenorphine Into HIV Treatment	Unknown status	NCT00241930	Phase 4
3	Transfer From Methadone to Buprenorphine Maintenance Treatment Using Buprenorphine Patches	Unknown status	NCT00750217	Phase 4	Buprenorphine patch and sublingual tablets
4	Determine the Safety of a Sublingual Tablet Formulation of Buprenorphine and Naloxone by Extending the Combination Tablet Availability to Physicians in Office-Based Practice	Completed	NCT00007527	Phase 4	naloxone;buprenorphine
5	Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence	Completed	NCT00555425	Phase 4
6	Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy	Completed	NCT01045278	Phase 4	Pegylated interferon-alfa-2b and ribavirin
7	Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence	Completed	NCT01903005	Phase 4	Higher bioavailability BNX sublingual tablets
8	Multicentre Trial of Suboxone in Opiate-dependent Subjects in Taiwan	Completed	NCT00901875	Phase 4	Buprenorphine + naloxone (Suboxone);Buprenorphine + naloxone (Suboxone)
9	Integrating Buprenorphine Into the SFGH AIDS Program	Completed	NCT00263458	Phase 4
10	Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14	Completed	NCT00015340	Phase 4	Buprenorphine/naloxone
11	Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population	Completed	NCT02038790	Phase 4	Suboxone Sublingual Film;Zubsolv sublingual tablets
12	A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration	Completed	NCT01453374	Phase 4	VIVITROL 380mg
13	Counseling for Primary Care Office-based Buprenorphine	Completed	NCT00595764	Phase 4
14	Effects of Ketamine On Precipitated Opioid Withdrawal Under General Anaesthesia	Completed	NCT00300794	Phase 4	Ketamine
15	Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients	Completed	NCT00879996	Phase 4	Methadone;Buprenorphine/naloxone
16	Intensive Outpatient Versus Outpatient Treatment With Buprenorphine Among African Americans	Completed	NCT01096550	Phase 4
17	A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED)	Completed	NCT00605033	Phase 4	Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484;Subutex, Buprenorphine Hydrochloride, SCH 28444
18	Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment	Completed	NCT00844272	Phase 4
19	Treatment of Polydrug-Using Opiate Dependents During Withdrawal	Completed	NCT00367874	Phase 4	Buprenorphine;Valproate
20	Relapse Prevention to Reduce HIV Among Women Prisoners	Completed	NCT00763958	Phase 4	Placebo;Buprenorphine
21	A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED)	Completed	NCT00604188	Phase 4	Suboxone (SCH 000484);Subutex (SCH 028444)
22	Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED)	Completed	NCT00684073	Phase 4	buprenorphine;buprenorphine/naloxone
23	Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM)	Completed	NCT00798538	Phase 4
24	Pre-Release VIVITROL for Opioid Dependent Inmates	Completed	NCT01563718	Phase 4	naltrexone for extended release injectable suspension
25	An Effectiveness Trial of Maintenance Therapy for Nicotine Dependence	Completed	NCT01047527	Phase 4	Transdermal nicotine patch
26	Desvenlafaxine in Opioid-Dependent Patients	Completed	NCT02200406	Phase 4	Desvenlafaxine
27	Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment	Completed	NCT02032433	Phase 4	Extended-Release Naltrexone;Buprenorphine-Naloxone
28	Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia	Completed	NCT02396979	Phase 4	Methadone
29	Naltrexone Treatment for Alcoholic Women	Completed	NCT00000448	Phase 4	naltrexone;Placebo
30	Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients	Completed	NCT01559454	Phase 4	Methadone;Buprenorphine/naloxone
31	Depot Naltrexone Mechanism of Action in Heroin Dependent Patients Using fMRI and SPECT	Completed	NCT01471145	Phase 4	Naltrexone
32	Buprenorphine and Integrated HIV Care	Completed	NCT00317460	Phase 4
33	Feasibility Study of Take-Home LAAM Medication - 3	Completed	NCT00000300	Phase 4	LAAM
34	Influence of Dexmedetomidine and Lidocaine on Opioid Consumption in Laparoscopic Intestine Resection	Completed	NCT02616523	Phase 4	Dexmedetomidine;Lidocaine;Fentanyl
35	A Comparison of PR Oxycodone/Naloxone and PR Oxycodone After Cardiac Surgery	Completed	NCT01374763	Phase 4	Oxycodone;Prolonged-release oxycodone/naloxone
36	Neurocognitive Effects of Opiate Agonist Treatment	Completed	NCT01733693	Phase 4	Buprenorphine;Methadone
37	Attention Training for Opioid-maintained Cocaine Users	Completed	NCT01870882	Phase 4
38	Effects of Buspirone in Opiate Withdrawal	Completed	NCT00326235	Phase 4	Buspirone
39	A Stepwise Strategy Utilizing Buprenorphine and Methadone	Completed	NCT00310934	Phase 4	methadone;buprenorphine / methadone sequence
40	A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic	Recruiting	NCT03235154	Phase 4	sofosbuvir/velpatasvir
41	Houston Emergency Opioid Engagement System	Recruiting	NCT03396276	Phase 4	Suboxone
42	Buprenorphine to Improve HIV Care Engagement and Outcomes (BRAVO)	Recruiting	NCT01936857	Phase 4	Buprenorphine/naloxone;Methadone Maintenance Therapy
43	Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings	Recruiting	NCT03089983	Phase 4	Naltrexone;Methadone;Isoniazid;Rifapentine
44	Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures	Recruiting	NCT03305666	Phase 4	Liposomal bupivacaine injection;Bupivacaine indwelling catheter
45	Switch to Genvoya Followed by HCV Therapy With Epclusa in Patients With HIV/HCV Co-Infection on Methadone	Recruiting	NCT03549312	Phase 4	Genvoya;Epclusa
46	Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry	Recruiting	NCT01999946	Phase 4	Extended-Release Naltrexone
47	Administration of Acetazolamide to Prevent Remifentanil Induced Hyperalgesia	Recruiting	NCT02992938	Phase 4	Acetazolamide;Placebo Oral Tablet
48	Biomarkers of Injectable Extended Release Naltrexone Treatment	Active, not recruiting	NCT02324725	Phase 4	Naltrexone
49	Extended Release Naltrexone for Opioid-Dependent Youth	Active, not recruiting	NCT01843023	Phase 4	Extended Release Naltrexone;Buprenorphine
50	Structured Discontinuation vs Continued Therapy in Suboptimal and Optimal Responders to High-dose Long-term Opioids for Chronic Pain	Active, not recruiting	NCT02741076	Phase 4	Morphine Sulfate ER;Oxycodone ER;Oxymorphone ER

Search NIH Clinical Center for Opiate Dependence

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :

clonidine hcl pwdr

clonidine hydrochloride

levomethadyl

levomethadyl acetate hydrochloride

methadone

methadone hydrochloride

nalmefene

nalmefene hydrochloride

naloxone hydrochloride

naltrexone

naltrexone hydrochloride

Cochrane evidence based reviews: opioid-related disorders

Sources

Genetic Tests for Opiate Dependence

Sources

Anatomical Context for Opiate Dependence

MalaCards organs/tissues related to Opiate Dependence:

⁴¹

Testes, Brain, Skin, Liver, Bone, Prefrontal Cortex, Cortex

Sources

Publications for Opiate Dependence

Articles related to Opiate Dependence:

(show top 50) (show all 249)

#	Title	Authors	Year
1	Opiate Dependence or Addiction?: A Review of the Centers for Disease Control and Prevention Guidelines for Management of Chronic Pain. ( 29505462 )	Dobbs G.C....Fogger S.A.	2018
2	Predicting health-related quality of life (EQ-5D-5A L) and capability wellbeing (ICECAP-A) in the context of opiate dependence using routine clinical outcome measures: CORE-OM, LDQ and TOP. ( 29843726 )	Peak J....Frew E.	2018
3	Breastfeeding support and opiate dependence: A think aloud study. ( 28494389 )	MacVicar S....Forbes-McKay K.E.	2017
4	Opiate dependence induces cell type-specific plasticity of intrinsic membrane properties in the rat juxtacapsular bed nucleus of stria terminalis (jcBNST). ( 28986608 )	Francesconi W....Sanna P.P.	2017
5	Regional cerebral blood flow in opiate dependence relates to substance use and neuropsychological performance. ( 28627790 )	Murray D.E....Meyerhoff D.J.	2017
6	Nonopiate Methods for Treatment of Opiate Dependence. ( 29368475 )	Hasan K.	2016
7	Frontal Metabolite Concentration Deficits in Opiate Dependence Relate to Substance Use, Cognition, and Self-Regulation. ( 27695638 )	Murray D.E....Meyerhoff D.J.	2016
8	Buprenorphine Maintenance Treatment of Opiate Dependence: Correlations Between Prescriber Beliefs and Practices. ( 26771870 )	MacDonald K....Khentigan W.	2016
9	A thalamic input to the nucleus accumbens mediates opiate dependence. ( 26840481 )	Zhu Y....Chen X.	2016
10	An economic evaluation of contingency management for completion of hepatitis B vaccination in those on treatment for opiate dependence. ( 26990598 )	Rafia R....Strang J.	2016
11	TPH1 and 5-HTTLPR Genes Specifically Interact in Opiate Dependence but Not in Alcohol Dependence. ( 27045756 )	Wang T.Y....Lu R.B.	2016
12	Measuring Health and Broader Well-Being Benefits in the Context of Opiate Dependence: The Psychometric Performance of the ICECAP-A and the EQ-5D-5L. ( 27712710 )	Goranitis I....Frew E.	2016
13	Influence of Psychiatric and Personality Disorders on Smoking Cessation Among Individuals in Opiate Dependence Treatment. ( 27064523 )	Cooperman N.A....Williams J.M.	2016
14	A prospective, longitudinal study of sleep disturbance and comorbidity in opiate dependence (the ANRS Methaville study). ( 26753792 )	Nordmann S....Carrieri M.P.	2016
15	Retention in Medication-Assisted Treatment for Opiate Dependence: A Systematic Review. ( 26467975 )	Timko C....Garrison-Diehn C.	2015
16	Role of Temperament, Personality Traits and Onset Age of Smoking in Predicting Opiate Dependence. ( 26870712 )	Amirabadi B....Safari H.	2015
17	Analysis of connectivity in NeuCube spiking neural network models trained on EEG data for the understanding of functional changes in the brain: A case study on opiate dependence treatment. ( 26000776 )	Capecci E....Wang G.Y.	2015
18	Evidence of anhedonia and differential reward processing in prefrontal cortex among post-withdrawal patients with prescription opiate dependence. ( 26711857 )	Huhn A.S....Bunce S.C.	2015
19	Interim Buprenorphine Treatment in Opiate Dependence: A Pilot Effectiveness Study. ( 26176490 )	Abrahamsson T....Hakansson A.	2015
20	Opiate dependence in schizophrenia: case presentation and literature review. ( 25392062 )	Kern A.M....Nordstrom B.R.	2014
21	Buprenorphine for opiate dependence: clinic based therapy in Israel. ( 25841225 )	Goren L....Marchevsky S.	2014
22	Opiate dependence induces network state shifts in the limbic system. ( 23911767 )	Dejean C....Le Moine C.	2013
23	Medication-assisted treatment of opiate dependence is gaining favor. ( 23733899 )	Jerry J.M....Collins G.B.	2013
24	Association between DRD2, 5-HTTLPR, and ALDH2 genes and specific personality traits in alcohol- and opiate-dependent patients. ( 23685324 )	Wang T.Y....Lu R.B.	2013
25	Social stress engages opioid regulation of locus coeruleus norepinephrine neurons and induces a state of cellular and physical opiate dependence. ( 23660707 )	Chaijale N.N....Valentino R.J.	2013
26	Opiate dependence as an independent and interactive risk factor for arterial stiffness and cardiovascular ageing - a longitudinal study in females. ( 23976908 )	Reece A.S....Hulse G.K.	2013
27	Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal. ( 23624062 )	Scavone J.L....Van Bockstaele E.J.	2013
28	Effects of opiate dependence through different administration routes on pulmonary inflammation and its severity. ( 24693370 )	Masoomi M....Abasi E.	2013
29	Manifold implications of forgotten hyperglycemia in clinical opiate dependence. ( 22313373 )	Reece A.S.	2013
30	Medically assisted recovery from opiate dependence within the context of the UK drug strategy: methadone and Suboxone (buprenorphine-naloxone) patients compared. ( 22703715 )	McKeganey N....Cockayne L.	2013
31	Enlarged cavum septum pellucidum as a neurodevelopmental marker in adolescent-onset opiate dependence. ( 24205275 )	Hwang J....Lyoo I.K.	2013
32	Take home maintenance medication in opiate dependence. ( 23837085 )	Gutwinski S....Gallinat J.	2013
33	Duration of opiate exposure as a determinant of arterial stiffness and vascular age in male opiate dependence: a longitudinal study. ( 24329809 )	Reece A.S....Hulse G.K.	2013
34	Receipt of prescribed controlled substances by adolescents and young adults prior to presenting for opiate dependence treatment. ( 24826367 )	Matson S.C....Bonny A.E.	2013
35	Elevated IGF1 in clinical opiate dependence. ( 23524620 )	Reece A.S.	2013
36	Exercise as an adjuvant intervention in opiate dependence. ( 23577897 )	Pareja-Galeano H....Mayero S.	2013
37	Relative and age-dependent stimulation of soluble and cellular immunity in opiate dependence. ( 21918466 )	Reece A.S.	2012
38	Differing age related trajectories of dysfunction in several organ systems in opiate dependence. ( 21339699 )	Reece A.S.	2012
39	Effect of craving induction on inhibitory control in opiate dependence. ( 21952672 )	Verdejo-GarcA-a A....YA1cel M.	2012
40	Premature ejaculation and other sexual dysfunctions in opiate dependent men receiving methadone substitution treatment. ( 21920671 )	Chekuri V....Krishnadas R.	2012
41	KPNA3 variation is associated with schizophrenia, major depression, opiate dependence and alcohol dependence. ( 22960338 )	Morris C.P....Voisey J.	2012
42	Alpha-synuclein and heroin craving in opiate-dependent patients on injectable heroin maintenance. ( 21309955 )	DA1rsteler-Macfarland K.M....Wiesbeck G.A.	2012
43	Ecological momentary assessment in alcohol, tobacco, cannabis and opiate dependence: a comparison of feasibility and validity. ( 22647899 )	Serre F....Swendsen J.	2012
44	Association of nerve growth factor and vascular endothelial growth factor A with psychometric measurements of opiate dependence: results of a pilot study in patients participating in a structured diamorphine maintenance program. ( 22517242 )	Heberlein A....Hillemacher T.	2012
45	The effect of pain on stroop performance in patients with opiate dependence in sustained remission. ( 21769047 )	Aniskin D.B....Galynker I.I.	2011
46	Deterioration of indices of aortic augmentation and vascular age predate major cardiac events and interact with opiate dependence. ( 19327850 )	Reece A.S.	2011
47	Functional imaging of emotion reactivity in opiate-dependent borderline personality disorder. ( 22448769 )	Smoski M.J....Linehan M.M.	2011
48	Pharmacological treatments of opiate dependence. ( 21524267 )	Benyamina A....Karila L.	2011
49	Serum levels of BDNF are associated with craving in opiate-dependent patients. ( 21890593 )	Heberlein A....Hillemacher T.	2011
50	Association between Novelty Seeking of opiate-dependent patients and the catechol-O-methyltransferase Val(158)Met polymorphism. ( 20728009 )	Demetrovics Z....Barta C.	2010

Sources

Genes for Opiate Dependence

Genes related to Opiate Dependence (1 elite genes):

(show all 15)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	ODS1	Opioid Dependence, Susceptibility To, 1	Genetic Locus	50	MalaCards inferred ⁵⁷
2	OPRM1	Opioid Receptor Mu 1	Protein Coding	26.61	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	12960749 17416470 15558714 (more) 12648891 17503481 18193922 16536895 20357116 9756053 18424454 19403243 9517399
3	DRD3	Dopamine Receptor D3	Protein Coding	24.29	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	9702743
4	OPRK1	Opioid Receptor Kappa 1	Protein Coding	22.42	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	9365966 9517399
5	CREB1	CAMP Responsive Element Binding Protein 1	Protein Coding	22.32	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	DRD2	Dopamine Receptor D2	Protein Coding	22.32	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	11054765 16583408 12497624 (more) 20305222 10881203 11256581
7	OPRD1	Opioid Receptor Delta 1	Protein Coding	22.27	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	17503481 20300121
8	PDYN	Prodynorphin	Protein Coding	22.12	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	9190848 16314761
9	SLC6A4	Solute Carrier Family 6 Member 4	Protein Coding	22.05	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	TH	Tyrosine Hydroxylase	Protein Coding	21.35	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	POMC	Proopiomelanocortin	Protein Coding	21.26	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	NGF	Nerve Growth Factor	Protein Coding	19.95	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	16.55	GeneCards inferred via : Publications (show sections)
14	TPH1	Tryptophan Hydroxylase 1	Protein Coding	16.55	GeneCards inferred via : Publications (show sections)
15	IGF1	Insulin Like Growth Factor 1	Protein Coding	16.55	GeneCards inferred via : Publications (show sections)

Sources

Variations for Opiate Dependence

Sources

Expression for Opiate Dependence

Search GEO for disease gene expression data for Opiate Dependence.

Sources

Pathways for Opiate Dependence

Pathways related to Opiate Dependence according to GeneCards Suite gene sharing:

(show all 15)

#	Super pathways	Score	Top Affiliating Genes
1	Signaling by GPCR ⁶⁶ Show member pathways GPCR downstream signaling ⁶⁶ Signal Transduction ⁶⁶	13.87	CREB1 DRD2 DRD3 IGF1 NGF OPRD1
2	Peptide ligand-binding receptors ⁶⁶ Show member pathways Class A/1 (Rhodopsin-like receptors) ⁶⁶ Defective AVP causes neurohypophyseal diabetes insipidus (NDI) ⁶⁶ Formyl peptide receptors bind formyl peptides and many other ligands ⁶⁶ G alpha (i) signalling events ⁶⁶ GPCR ligand binding ⁶⁶ GPCRs, Class A Rhodopsin-like ¹ Neuroactive ligand-receptor interaction ³⁷ Orexin and neuropeptides FF and QRFP bind to their respective receptors ⁶⁶ Peptide GPCRs ¹ Tachykinin receptors bind tachykinins ⁶⁶ Vasopressin-like receptors ⁶⁶	13.31	DRD2 DRD3 OPRD1 OPRK1 OPRM1 PDYN
3	DAG and IP3 signaling ⁶⁶ Show member pathways Beta-2 adrenergic-dependent CFTR expression ²² Ca-dependent events ⁶⁶ Calmodulin induced events ⁶⁶ CaM pathway ⁶⁶ Cam-PDE 1 activation ⁶⁶ CREB phosphorylation through the activation of Adenylate Cyclase ⁶⁶ Development Beta-adrenergic receptors signaling via cAMP ²² Development Role of Activin A in cell differentiation and proliferation ²² EGFR interacts with phospholipase C-gamma ⁶⁶ G Protein Signaling Pathways ¹ G-protein mediated events ⁶⁶ Inhibitory action of Lipoxin A4 on PDGF, EGF and LTD4 signaling ²² Neurophysiological process PGE2-induced pain processing ²² Opioid Signalling ⁶⁶ PKA activation ⁶⁶ PKA activation in glucagon signalling ⁶⁶ PKA-mediated phosphorylation of CREB ⁶⁶ PLC beta mediated events ⁶⁶ PLC-gamma1 signalling ⁶⁶ Signal transduction Calcium signaling ²²	12.86	CREB1 NGF OPRM1 PDYN POMC
4	Circadian entrainment ³⁷ Show member pathways Cholinergic synapse ³⁷ Dopaminergic synapse ³⁷ Estrogen signaling pathway ³⁷ Glutamatergic synapse ³⁷ Relaxin receptors ⁶⁶ Relaxin signaling pathway ³⁷ Synaptic Neurotransmission Pathways: Glutamatergic Excitation ⁶⁵	12.75	CREB1 DRD2 DRD3 OPRM1 TH VEGFA
5	ADP signalling through P2Y purinoceptor 12 ⁶⁶ Show member pathways Adrenaline,noradrenaline inhibits insulin secretion ⁶⁶ Beta-agonist/Beta-blocker Pathway, Pharmacodynamics ⁶¹ Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding ⁶⁶ G alpha (z) signalling events ⁶⁶ G-protein activation ⁶⁶ Signal transduction cAMP signaling ²²	12.28	CREB1 OPRM1 PDYN POMC
6	Neuroscience ⁴	12.17	CREB1 NGF OPRM1 POMC TH TPH1
7	Circadian rythm related genes ¹	11.75	CREB1 DRD2 DRD3 SLC6A4 TH TPH1
8	Amphetamine addiction ³⁷ Show member pathways Cocaine addiction ³⁷	11.74	CREB1 DRD2 PDYN TH
9	Interleukin-4 and 13 signaling ⁶⁶	11.68	OPRD1 OPRM1 POMC VEGFA
10	Nicotine Pathway (Dopaminergic Neuron), Pharmacodynamics ⁶¹ Show member pathways Nicotine Activity on Dopaminergic Neurons ¹ SNARE interactions in vesicular transport ³⁷	11.64	DRD2 DRD3 TH
11	Neural Stem Cell Differentiation Pathways and Lineage-specific Markers ⁶⁵	11.46	IGF1 NGF TH VEGFA
12	Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways ¹	11.31	CREB1 NGF SLC6A4 TH TPH1 VEGFA
13	Biogenic Amine Synthesis ¹ Show member pathways catecholamine biosynthesis ¹ Catecholamine biosynthesis ⁶⁶	10.88	TH TPH1
14	DARPP-32 Phosphorylation ⁶⁵	10.87	DRD2 DRD3
15	p38 signaling mediated by MAPKAP kinases ¹	10.81	CREB1 TH

Sources

GO Terms for Opiate Dependence

Cellular components related to Opiate Dependence according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	axon	GO:0030424	9.72	CREB1 DRD2 NGF OPRM1 TH
2	dendrite	GO:0030425	9.63	DRD2 NGF OPRK1 OPRM1 PDYN TH
3	perikaryon	GO:0043204	9.56	DRD2 OPRK1 OPRM1 TH
4	neuron projection	GO:0043005	9.43	OPRD1 OPRK1 OPRM1 SLC6A4 TH TPH1
5	axon terminus	GO:0043679	8.92	DRD2 OPRD1 OPRK1 PDYN

Biological processes related to Opiate Dependence according to GeneCards Suite gene sharing:

(show top 50) (show all 60)

#	Name	GO ID	Score	Top Affiliating Genes
1	cytokine-mediated signaling pathway	GO:0019221	9.99	OPRD1 OPRM1 POMC VEGFA
2	chemical synaptic transmission	GO:0007268	9.97	OPRD1 OPRK1 OPRM1 PDYN
3	response to drug	GO:0042493	9.97	CREB1 DRD2 DRD3 SLC6A4 TH
4	response to organic substance	GO:0010033	9.86	CREB1 IGF1 SLC6A4
5	circadian rhythm	GO:0007623	9.85	CREB1 SLC6A4 TPH1
6	phospholipase C-activating G-protein coupled receptor signaling pathway	GO:0007200	9.83	OPRD1 OPRK1 OPRM1
7	response to hypoxia	GO:0001666	9.83	CREB1 DRD2 SLC6A4 TH VEGFA
8	G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	GO:0007187	9.82	OPRD1 OPRK1 OPRM1
9	adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway	GO:0007193	9.82	OPRD1 OPRK1 OPRM1
10	cellular response to growth factor stimulus	GO:0071363	9.81	CREB1 OPRD1 TH
11	sensory perception of pain	GO:0019233	9.81	OPRD1 OPRK1 OPRM1
12	social behavior	GO:0035176	9.79	DRD3 SLC6A4 TH
13	visual learning	GO:0008542	9.79	CREB1 DRD2 DRD3
14	memory	GO:0007613	9.78	CREB1 NGF SLC6A4 TH
15	response to nicotine	GO:0035094	9.77	CREB1 DRD2 TH
16	positive regulation of receptor internalization	GO:0002092	9.73	DRD2 VEGFA
17	response to immobilization stress	GO:0035902	9.73	TH TPH1
18	regulation of sensory perception of pain	GO:0051930	9.73	OPRD1 OPRK1 OPRM1
19	regulation of dopamine secretion	GO:0014059	9.72	DRD2 DRD3
20	dopamine receptor signaling pathway	GO:0007212	9.72	DRD2 DRD3
21	positive regulation of neuroblast proliferation	GO:0002052	9.72	DRD2 VEGFA
22	positive regulation of Ras protein signal transduction	GO:0046579	9.72	IGF1 NGF
23	response to ethanol	GO:0045471	9.72	DRD2 DRD3 OPRK1 OPRM1 TH
24	eye photoreceptor cell development	GO:0042462	9.71	TH VEGFA
25	positive regulation of long-term synaptic potentiation	GO:1900273	9.71	CREB1 DRD2
26	negative regulation of protein secretion	GO:0050709	9.71	DRD2 DRD3
27	mammary gland alveolus development	GO:0060749	9.71	TPH1 VEGFA
28	response to growth factor	GO:0070848	9.71	OPRM1 TH
29	estrous cycle	GO:0044849	9.7	OPRK1 OPRM1
30	positive regulation of CREB transcription factor activity	GO:0032793	9.7	OPRD1 VEGFA
31	behavioral response to ethanol	GO:0048149	9.7	DRD2 OPRM1
32	dopamine metabolic process	GO:0042417	9.7	DRD2 DRD3
33	response to amphetamine	GO:0001975	9.7	DRD2 DRD3 TH
34	positive regulation of renal sodium excretion	GO:0035815	9.69	DRD2 DRD3
35	neurotransmitter biosynthetic process	GO:0042136	9.69	SLC6A4 TH
36	behavioral response to cocaine	GO:0048148	9.69	DRD2 DRD3 OPRK1
37	prepulse inhibition	GO:0060134	9.68	DRD2 DRD3
38	G-protein coupled receptor internalization	GO:0002031	9.68	DRD2 DRD3
39	adenylate cyclase-inhibiting dopamine receptor signaling pathway	GO:0007195	9.67	DRD2 DRD3
40	synaptic transmission, dopaminergic	GO:0001963	9.67	DRD2 DRD3 TH
41	response to cocaine	GO:0042220	9.67	DRD2 DRD3 OPRK1 OPRM1
42	adenylate cyclase-activating dopamine receptor signaling pathway	GO:0007191	9.66	DRD3 OPRM1
43	aromatic amino acid family metabolic process	GO:0009072	9.66	TH TPH1
44	neuropeptide signaling pathway	GO:0007218	9.65	OPRD1 OPRK1 OPRM1 PDYN POMC
45	sensory perception	GO:0007600	9.63	OPRK1 OPRM1 PDYN
46	regulation of dopamine uptake involved in synaptic transmission	GO:0051584	9.62	DRD2 DRD3
47	acid secretion	GO:0046717	9.59	DRD2 DRD3
48	negative regulation of dopamine receptor signaling pathway	GO:0060160	9.58	DRD2 DRD3
49	response to histamine	GO:0034776	9.58	DRD2 DRD3
50	opioid receptor signaling pathway	GO:0038003	9.58	OPRD1 OPRK1 OPRM1

Molecular functions related to Opiate Dependence according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	G-protein coupled receptor activity	GO:0004930	9.85	DRD2 DRD3 OPRD1 OPRK1 OPRM1
2	obsolete signal transducer activity	GO:0004871	9.73	DRD2 DRD3 OPRD1 OPRM1
3	peptide binding	GO:0042277	9.54	OPRD1 OPRK1 OPRM1
4	dopamine neurotransmitter receptor activity, coupled via Gi/Go	GO:0001591	9.4	DRD2 DRD3
5	neuropeptide binding	GO:0042923	9.33	OPRD1 OPRK1 OPRM1
6	dopamine neurotransmitter receptor activity	GO:0004952	9.32	DRD2 DRD3
7	oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen	GO:0016714	9.26	TH TPH1
8	dopamine binding	GO:0035240	9.13	DRD2 DRD3 TH
9	opioid receptor activity	GO:0004985	8.8	OPRD1 OPRK1 OPRM1

Sources

Sources for Opiate Dependence

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia

Opiate Dependence

Aliases & Classifications for Opiate Dependence

MalaCards integrated aliases for Opiate Dependence:

Classifications:

External Ids:

Summaries for Opiate Dependence

Related Diseases for Opiate Dependence

Diseases related to Opiate Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Opiate Dependence:

Symptoms & Phenotypes for Opiate Dependence

MGI Mouse Phenotypes related to Opiate Dependence:

Drugs & Therapeutics for Opiate Dependence

Drugs for Opiate Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 73 / NDF-RT 51 :

Cochrane evidence based reviews: opioid-related disorders

Genetic Tests for Opiate Dependence

Anatomical Context for Opiate Dependence

MalaCards organs/tissues related to Opiate Dependence:

Publications for Opiate Dependence

Articles related to Opiate Dependence:

Genes for Opiate Dependence

Genes related to Opiate Dependence (1 elite genes):

Variations for Opiate Dependence

Expression for Opiate Dependence

Pathways for Opiate Dependence

Pathways related to Opiate Dependence according to GeneCards Suite gene sharing:

GO Terms for Opiate Dependence

Cellular components related to Opiate Dependence according to GeneCards Suite gene sharing:

Biological processes related to Opiate Dependence according to GeneCards Suite gene sharing:

Molecular functions related to Opiate Dependence according to GeneCards Suite gene sharing:

Sources for Opiate Dependence

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :